Research Analysts’ Recent Ratings Changes for Definitive Healthcare (DH)

Several brokerages have updated their recommendations and price targets on shares of Definitive Healthcare (NASDAQ: DH) in the last few weeks:

• 3/14/2026 – Definitive Healthcare was upgraded by Wall Street Zen from “hold” to “buy”.
• 3/5/2026 – Definitive Healthcare was downgraded by Zacks Research from “hold” to “strong sell”.
• 2/28/2026 – Definitive Healthcare was downgraded by Wall Street Zen from “buy” to “hold”.
• 2/27/2026 – Definitive Healthcare had its price target lowered by Canaccord Genuity Group Inc. from $4.00 to $3.00. They now have a “hold” rating on the stock.
• 2/27/2026 – Definitive Healthcare had its price target lowered by Stephens from $3.00 to $2.00. They now have an “equal weight” rating on the stock.
• 1/21/2026 – Definitive Healthcare had its “sell (d-)” rating reaffirmed by Weiss Ratings.

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.